Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438383 | 1.00 | MAOA (0.45) | MAOAMAOBGAANPSR1ALDH1A1 | |
| SCHEMBL311687 | 0.85 | MAOB (0.39) | MAOAMAOBGAANPSR1RAB9A | |
| SCHEMBL3212349 | 0.81 | TP53 (0.43) | ALDH1A1NPC1RAB9ALMNAKDM4E | |
| SCHEMBL30098325 | 0.81 | MAOA (0.42) | MAOAMAOBGAANPSR1ALDH1A1 | |
| SCHEMBL6567554 | 0.81 | MAOA (0.42) | MAOAMAOBGAANPSR1ALDH1A1 | |
| SCHEMBL1932339 | 0.79 | AHR (0.42) | ALDH1A1NPC1RAB9ALMNAMAPT | |
| SCHEMBL6622506 | 0.77 | PTGS2 (0.47) | ALDH1A1NPC1RAB9ALMNAKDM4E | |
| SCHEMBL13820527 | 0.76 | LTB4R (0.34) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL7683234 | 0.74 | PDE4A (0.41) | NPSR1ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL9200401 | 0.73 | ALDH1A1 (0.34) | ALDH1A1LMNAKDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119842767-A | Recombinant expression vector for synthesizing outer membrane protein of cyanidin-3-O-glucoside, recombinant microorganism and preparation method thereof | 陕西科技大学 | 2025-04-18 | — | — | CN | claimed |
| CN-116656710-A | Application of multidrug resistance transporter MdtH in synthesis of cyanidin-3-O-glucoside | 陕西科技大学 | 2023-08-29 | — | — | CN | claimed |
| EP-2282734-A2 | METHOD FOR PROTECTING HUMANS AGAINST SUPERFICIAL VASODILATOR FLUSH SYNDROME | Theta Biomedical Consulting & Development Co., Inc. (US) | 2011-02-16 | — | — | EP | claimed |
| EP-2229056-A1 | COMPOSITIONS FOR PROTECTION AGAINST SUPERFICIAL VASODILATOR FLUSH SYNDROME, AND METHODS OF USE | Theta Biomedical Consulting & Development Co., Inc. (US) | 2010-09-22 | — | — | EP | claimed |
| US-7651692-B2 | Skin disorders; cosmetics; aging resistance | COGNIS FRANCE S.A. (FR) | 2010-01-26 | — | — | US | claimed |
| WO-2009137510-A2 | METHOD FOR PROTECTING HUMANS AGAINST SUPERFICIAL VASODILATOR FLUSH SYNDROME | THETA BIOMEDICAL CONSULTING & DEVELOPMENT CO., INC (US) | 2009-11-12 | — | — | WO | claimed |
| WO-2009076353-A1 | COMPOSITIONS FOR PROTECTION AGAINST SUPERFICIAL VASODILATOR FLUSH SYNDROME, AND METHODS OF USE | THE BIOMEDICAL CONSULTING & DEVELOPMENT CO., INC. (US) | 2009-06-18 | — | — | WO | claimed |
| US-20090148543-A1 | Method for protecting humans against superficial vasodilator flush syndrome, | THETA BIOMEDICAL CONSULTING AND DEVELOPMENT, LLC | 2009-06-11 | — | — | US | claimed |
| US-20080153761-A1 | Compositions for protection against superficial vasodilator flush syndrome, and methods of use | THETA BIOMEDICAL CONSULTING & DEVELOPMENT CO., INC. | 2008-06-26 | — | — | US | claimed |
| US-20070141187-A1 | Treating niacin-induced flush by administering a a synergistic mixture of non-bovine sulfated proteoglycan, olive kernel oil, and quercetin or luteolin. | THETA BIOMEDICAL CONSULTING AND DEVELOPMENT, LLC | 2007-06-21 | — | — | US | claimed |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2006-02-16 | — | — | US | claimed |
| US-20040242503-A1 | Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease | ATTENTION LABS INCORPORATED | 2004-12-02 | — | — | US | claimed |
| EP-1267853-B1 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & CA SA (PT) | 2004-09-08 | — | — | EP | claimed |
| EP-1267853-A2 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | Portela & Ca., S.A. (PT) | 2003-01-02 | — | — | EP | claimed |
| WO-2001068065-A9 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & CA SA (PT) | 2002-07-18 | — | — | WO | claimed |
| WO-2001068065-A2 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & COMPANHIA S.A. (PT) | 2001-09-20 | — | — | WO | claimed |
| CN-121054755-B | Low-temperature-resistant flow battery electrolyte, preparation method and zinc-bromine flow battery | 西安热工研究院有限公司 | 2026-02-10 | — | — | CN | disclosed |
| CN-121054755-A | Low-temperature-resistant flow battery electrolyte, preparation method and zinc-bromine flow battery | 西安热工研究院有限公司 | 2025-12-02 | — | — | CN | disclosed |
| EP-0178633-B1 | 2-phenylpyrano[2,3-b]pyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0348121-A1 | Process for the synthesis of anthocyanidines and novel intermediates produced in said processes | IDB HOLDING S.p.A. (IT) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242503-A1 | Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease | COMT, DDC, AADAT | MAOA 142/4885MAOB 23/4885GAA 283/4885 |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP4, CASP3, CASP7 | MAOA 1956/4885MAOB 2265/4885GAA 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.